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Abstract
Background: Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has previously been demonstrated
to play a pro-inflammatory role in allergic airways disease and COPD through the upregulation of the E3 ubiquitin
ligase MID1 and the subsequent deactivation of protein phosphatase 2A (PP2A).
Methods: Biopsies were taken from eight IPF patients presenting to the Second Affiliated Hospital of Jilin University,
China between January 2013 and February 2014 with control samples obtained from resected lung cancers. Serum
TRAIL, MID1 protein and PP2A activity in biopsies, and patients’ lung function were measured. Wild type and TRAIL
deficient Tnfsf10−/− BALB/c mice were administered bleomycin to induce fibrosis and some groups were treated with
the FTY720 analogue AAL(s) to activate PP2A. Mouse fibroblasts were treated with recombinant TRAIL and fibrotic
responses were assessed.
Results: TRAIL in serum and MID1 protein levels in biopsies from IPF patients were increased compared to controls.
MID1 levels were inversely associated while PP2A activity levels correlated with DLco. Tnfsf10−/− and mice treated with
the PP2A activator AAL(s) were largely protected against bleomycin-induced reductions in lung function and fibrotic
changes. Addition of recombinant TRAIL to mouse fibroblasts in-vitro increased collagen production which was
reversed by PP2A activation with AAL(s).
Conclusion: TRAIL signalling through MID1 deactivates PP2A and promotes fibrosis with corresponding lung function
decline. This may provide novel therapeutic targets for IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is the most com-
mon form of the idiopathic interstitial lung disorders
accounting for 50–60% of cases [1]. There is marked
heterogeneity in the histopathological findings, radio-
logical profiles, treatment responsiveness and the rate
of disease progression across individuals diagnosed
with IPF. This is thought to be due to the complexity
of the interplay between environmental and endogen-
ous factors and the multiplicity of co-activated
pathogenic pathways that have been demonstrated to
underpin this disease [2].
IPF consistently clinically manifests as chronic and
progressive exertional dyspnoea and dry cough of grad-
ual onset as a result of restrictive ventilation impairment
and respiratory failure [1]. Current medical interventions
for IPF are either supportive therapy (oxygen therapy) or
lung transplantation, and few effective pharmacological
therapies are available for its treatment. IPF has a poor
prognosis with a median survival of 3 years and a 5 year
survival rate of 45% [3]. The traditional concept of IPF
pathogenesis was that the initial event is an inflamma-
tory process characterised by infiltration of inflammatory
cells such as macrophages, lymphocytes and neutrophils
in the alveoli (alveolitis). Inflammation was believed to
lead to recruitment of fibroblasts and myofibroblasts
and finally to collagen formation and irreversible
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fibrosis. However, clinical trials of drugs inhibiting an
underpinning inflammatory process such as Etanercept,
a TNF-α antagonist, have consistently failed to show any
efficacy in slowing disease progression [4]. In contrast,
antifibrotic drugs such as nintedanib and pirfenidone
have been demonstrated to slow disease progression and
have recently been approved for use in treatment of
IPF in the USA and Europe [5, 6]. Thus, the current
consensus is that IPF is a primary epithelial and fi-
broblastic disease, and pro-inflammatory and inflam-
matory mediators are involved in the epithelial-dependent
fibrotic pathway.
Tumour necrosis factor-related apoptosis-inducing lig-
and (TRAIL) is a member of the tumour necrosis factor
family that is principally expressed by airway epithelial
cells [7, 8], and leukocytes including monocytes [9],
macrophages [10], lymphocytes [11] and neutrophils
[12]. It is best described for its role in inducing apoptosis
in a variety of transformed cells [13–15]; however, we
have recently described the fibrogenic role played by
TRAIL signalling in mouse models of allergic and neo-
natal infection-induced airways disease and in eosino-
philic esophagitis [16–18]. We have also shown that
TRAIL induces the E3 ubiquitin ligase midline-1 (Mid1)
to inhibit the activation status of the protein phosphat-
ase (PP)2A by interacting with the α4 regulatory subunit
that is required for the ubiquitin-specific modification
and proteasome-mediated degradation of its catalytic
subunit PP2Ac [19–21]. PP2A is the most abundant cel-
lular protein phosphatase. Reduced activity due to Mid1
upregulation resulted in hyperphosphylation of mitogen-
activated protein kinases (MAPKs) and inhibitor of κBα
(IκBα) protein, thereby promoting p38 MAPK, c-Jun
N-terminal kinase (JNK) and nuclear factor-κB (NF-κB)
activity [22–26].
Here we investigate lung tissue derived from IPF pa-
tients for the pro-inflammatory fibrogenic upregulation
of MID1 and PP2A. We also investigate the role of
TRAIL-Mid1-PP2A signalling in the rodent fulminant-
induced bleomycin model of pulmonary fibrosis and ex-
plore its relevance to collagen production by lung fibro-
blasts - thought to underpin much of the disease
phenotype in human disease.
Methods
Lung biopsies were collected from eight IPF patients
from the Department of Respiratory and Critical Care
Medicine, the Second Affiliated Hospital of Jilin Univer-
sity between January 2013 and February 2014. A clinical
diagnosis of IPF was identified according to histological
confirmation of usual interstitial pneumonia (UIP) or
the presence of a UIP pattern on high-resolution com-
puted tomography (HRCT). A total of 21 candidates with-
out known ILD (eg. environmental factors, occupational
exposure, connective tissue diseases, drug injury) under-
went blood tests for screening of connective tissues dis-
eases (including; ANCA, ANA, rheumatic blood test,
complement C3,C4) and upon negative results underwent
HRCT. Six patients were categorized as definite UIP and 4
as not UIP from the HRCT and did not undergo trans-
bronchoscopic biopsy. The remaining 11 patients classi-
fied as possible UIP according to the ATS/ERS/JRS/ALAT
statement criteria underwent transbronchosopic biopsy of
which eight had histologically confirmed UIP. The ATS/
ERS/JRS/ALAT guidelines state that “the sensitivity and
specificity of this approach (transbronchosopic biopsy) for
the diagnosis for UIP pattern is unknown” and therefore
not always suitable for the diagnosis of IPF. However, in
each of the eight cases here the diagnosis of IPF was made
on the basis of all features present (clinical parameters,
CT images, histology). Importantly, control tissues were
from tissues distal to resected lung cancer in patients with
no clinical evidence of IPF or other fibrotic lung disease.
Written informed consent was obtained from individual
subjects, and all the studies were approved by the Medical
Ethics Committee of the Second Affiliated Hospital of Jilin
University, Changchun, Jilin, P.R. China.
Mice
Wild-type (WT) and TRAIL deficient (Tnfsf10−/−) male
BALB/c mice (6–14 weeks-old) were obtained from the
Australian Bioresources facility (Moss Vale, Australia).
Animals were housed with ad libitum access to food and
water with a 12-h light-and-dark cycle.
Bleomycin-induced pulmonary fibrosis
Mice were anaesthetised with Alfaxan by tail vein injec-
tion, then 50 μl solution containing bleomycin (2 mg/kg,
Sigma-Aldrich, USA) was intratrachealy administered.
Control mice were administered saline instead. All pro-
cedures were performed in a sterile environment [27]. In
order to activate PP2A, mice received the nonphosphor-
ylatable FTY720 analog, (S)-2-amino-4-(4-heptyloxyphe-
nyl)-2-methylbutan-1-ol (AAL(s)) intranasaly starting at
day − 1 and daily throughout the model with bleomycin
administration at day 0. Mice were sacrificed 1, 4, 8, or
21 days after bleomycin instillation via pentobarbitone
overdose, and one lung was taken for histology and one
was homogenised for protein quantification.
Lung capacity
Vital capacity was assessed under Ketamine and Xyla-
zine induced anaesthesia, as the volume of air that en-
tered the lungs when the airway pressure was increased
from 2 to 30 cmH2O by the ventilator (PVs-P Flexivent
manoeuvre). Compliance was calculated as the measured
change in volume divided by this applied pressure
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change. Three inflations were performed and averaged
per mouse [27, 28].
Histological preparations
Lungs were collected in 10% neutral buffered formalin
solution for 24 h before being transferred to 70% etha-
nol. Tissue was then embedded in paraffin and stained
with either hematoxylin and eosin (eosinophils), periodic
acid Schiff (PAS positive mucus producing epithelial
cells), Masson’s Trichrome (Collagen), toluidine blue
(mast cells) or processed further for immunohistochem-
istry. Lungs across experimental groups were all proc-
essed as a batch for either histologic staining or the
immunostaining protocol.
Collagen area enumeration
The area of peribronchial trichrome staining in a
paraffin-embedded lung was outlined and quantified
using a light microscope (Olympus) attached to an
image-analysis system (Image-Pro Plus 6; Media Cyber-
netics, Maryland, USA). Results are expressed as the
area of trichrome staining per micrometre length of
basement membrane of major airways. At least 10
counts were made from each mouse as previously de-
scribed [17, 29].
Terminal dUTP nick end labelling (TUNEL) assay
Longitudinal sections of the left single-lobe lung were
stained with TUNEL assay kits (Promega, Sydney,
Australia) according to the manufacturer’s instructions.
Apoptosis in lung parenchyma was assessed by enu-
merating the numbers of TUNEL positive and nega-
tive cells in 20 randomised, 100mm2 fields by light
microscopy [28].
Quantitative RT-PCR
We performed quantitative RT-PCR with SYBR Green
(Invitrogen, Sydney, Australia) on a Realcycler (Eppen-
dorf, Sydney, Australia) with the following cycling condi-
tions: 2 min at 50 °C followed by 2 min at 95 °C.
Amplification was recorded during 40 cycles of 15 s at
95 °C followed by 45 s at 60 °C. We quantified mRNA
copy number using cDNA standards for all genes of
interest. We normalised expression to the housekeeping
gene Hprt with all primer sequences previously de-
scribed [22].
Elisa
Concentrations of human MID1 (Cusabio, USA) and
PP2A activity (R&D systems, USA) in homogenized lung
biopsies and TRAIL (R&D systems, USA) in serum were
determined using a sandwich ELISA according to the
manufacturer’s instructions [30, 31].
Primary mouse fibroblast culture
Lung tissue was collected under sterile conditions and
cut into approximately 1 × 1 mm tissue fragments. They
were washed three times with PBS and then spread on
the bottom of 6-well plates in complete DMEM with
10% (vol/vol) FCS. The media was changed every 2–3
days. Cell monolayers formed around tissue blocks in 1–
2 weeks. Tissue fragments were removed using sterile
forceps if more than 60% of the plate was covered by at-
tached fibroblasts. When fibroblasts reached > 90% con-
fluence, 0.25% trypsin was used to lift the cells, which
were then removed in two culture flasks for passage
(1:2). Fibroblasts were passaged 3 times with this
method. We used passage 4 and cultured them until
80% confluence, serum-starved them for 24 h and incu-
bated them with recombinant (r)TRAIL (0 ng/ml-100
ng/ml) for 24 h in serum-free DMEM.
Statistical analysis
Statistical significance was analysed using Student’s t-test
or Mann-Whitney test as appropriate. All graphed data
are expressed as mean ± SEM. Correlation analysis was
done using a Spearman test. All data was analysed using
GraphPad Prism 7 (La Jolla, CA).
Results
IPF diagnosis
Patients with a diagnosis of IPF as expected had a re-
duced percentage predicted carbon monoxide diffusing
capacity (% pred DLco) and forced vital capacity (% pred
FVC) (Table 1). Controls had normal DLCO and FVC.
Transbronchial biopsy sections for IPF patients had dis-
torted lung architecture and obliterated alveolar struc-
ture with hyperplastic pneumocytes, inflammation and
fibroblast proliferation (Fig. 1).
TRAIL in serum and MID1 protein in biopsies are
increased in IPF
We assessed protein levels of TRAIL in the serum and
MID1 and phosphatase activity of PP2A in homogenised
lung specimens compared to controls. We found that
TRAIL and MID1 protein levels were significantly upreg-
ulated in IPF patients (Fig. 2a, b). As expected, IPF pa-
tients had a reduced percentage predicted carbon
Table 1 Participant demographics for the control and IPF
populations included in the study
Control IPF p value
Gender (male/ total) 5/8 5/8
Age (min-max) 56 (45–62) 65 (50–83) 0.08
dLCo (25th–75th) 92.27 (89.2–96.53) 43.85 (28.73–53.73) < 0.001
FVC (25th – 75th) 79.85 (78.5–80.8) 44.2 (28.75–51.5) < 0.001
Smokers 2/8 3/8
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monoxide diffusing capacity (% pred DLco) (Table 1). Not-
ably MID1 protein and PP2A activity levels in lung biop-
sies from IPF patients correlated with DLco (Fig. 2e, f ).
Elevated Mid1 and reduced PP2A activity occurs in
bleomycin-induced pulmonary fibrosis, and the absence
of TRAIL or activation of PP2A reverses these effects and
improve lung function
We then assessed a mouse model of lung fibrosis in-
duced by bleomycin. In support of the human data WT
BALB/c mice with bleomycin-induced lung fibrosis dis-
played a marked upregulation of Mid1 and a downregu-
lation of PP2A activity in their lungs (Fig. 3a, b).
Furthermore, WT mice treated with the synthetic PP2A
activator AAL(s) and Tnfsf10−/− mice were protected
from the upregulation of Mid1 and the deactivation of
PP2A in response to bleomycin exposure (Fig. 3a, b).
WT mice treated with AAL(s) and Tnfsf10−/− mice were
also protected from the bleomycin-induced decline in
lung function as shown by an unaffected vital capacity
Fig. 1 Lung and alveolar structure is disrupted, and inflammatory responses occur in IPF. Representative images of haematoxylin and eosin stained
transbronchial biopsy sections at 200x magnification with arrows highlighting described features: Normal lung architecture from control patients (a),
distortion of the normal lung architecture and obliteration of alveolar architecture consistent with IPF (b), hyperplasic pneumocytes (c), inflammatory
infiltrates (d), and fibroblastic proliferation (e, f). Representative high-sresolution computerised-tomography image showing areas of air-space
consolidation, ground glass opacities, small nodular opacities and bronchial wall thickening and dilatation (g)
Collison et al. BMC Pulmonary Medicine           (2019) 19:31 Page 4 of 11
(VC) and peak compliance in response to bleomycin ex-
posure (Fig. 3c, d).
Pro-fibrotic factor mRNA levels are increased in bleomycin-
induced pulmonary fibrosis in mice, and the absence
of TRAIL or activation of PP2A reverses these effects
We next investigated the expression of pro-fibrotic factors
and found that bleomycin-exposed WT mice had elevated
levels of collagen-α2(I), transforming growth factor β1
(TGFβ), matrix metalloproteinase (MMP) 9 and C-C
motif chemokine ligand (CCL) 2 mRNA. AAL(s) treated
WT mice and Tnfsf10−/− mice were protected from the in-
creases in these pro-fibrotic mediators (Fig. 4).
Collagen deposition and apoptosis levels are increased in
bleomycin-induced pulmonary fibrosis in mice, and the
absence of TRAIL and activation of PP2A reverses these
effects
We then investigated the levels of collagen deposition
and apoptosis. Histological investigation of Masson’s tri-
chrome stained transverse lung sections demonstrated
that bleomycin induced increases in collagen deposition
around the airways compared to saline treated controls
(Fig. 5a). AAL(s) treated WT mice and Tnfsf10−/− mice
had reduced or inhibited collagen deposition, respect-
ively. TUNEL staining also revealed that bleomycin in-
duced increases in the percentage of TUNEL positive
cells that peaked after one day but was still elevated after
Fig. 2 Serum from IPF patients had elevated levels of TRAIL (a) and lung biopsies elevated MID1 (b) protein, which corresponded with a trend
towards decreased activity of PP2A (c) when compared to those from control subjects. The percentage predicted diffusing lung capacity for carbon
monoxide (DLco) did not have a strong inverse association with serum TRAIL (d) but was inversely associated with MID1 protein (e) and correlated
with the levels of PP2A activity (f) in lung biopsies from IPF patients. n = 8, * p < 0.05
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21 days (Fig. 5b, c). AAL(s) treated WT mice and
Tnfsf10−/− mice have reduced levels of TUNEL positive
staining.
Proliferation and release of Mid1 and collagen-α2(I) mRNA
were increased in mouse lung fibroblasts treated with
rTRAIL
Next, we isolated fibroblasts from mouse lungs and cul-
tured them with increasing concentrations of rTRAIL
in-vitro. Over 24 h we found that proliferation of fibro-
blasts increased in the presence of TRAIL in a
dose-dependent manner peaking at a dose of 1 ng/ml
(data not shown). This dose was sufficient to induce the
expression of Mid1 and collagen-α2(I) in fibroblast cul-
tures, while collagen expression but not Mid1 was inhib-
ited by addition of AAL(s) (Fig. 6 a, b).
Discussion
We have previously demonstrated that TRAIL signalling
through the ubiquitin ligase Mid1 and dysregulation of
PP2A activity plays a key role in lung fibrosis in house
dust mite and ovalbumin-induced allergic airways
disease models [17, 22, 32]. The pro-inflammatory
TRAIL pathway also is required for fibrosis in Aspergil-
lus fumigatus and ovalbumin-induced models of eosino-
philic oesophagitis and cigarette smoke induced models
of COPD [16, 28, 33].
Here we show that TRAIL and MID1 are associated
with pathogenesis and remodelling in IPF. TRAIL in pa-
tient serum and MID1 in the lungs of patients with ac-
tive IPF are both upregulated (Fig. 2a, b). MID1 protein
had an inverse correlation to lung function DLco in
these IPF patients (Fig. 2e) while levels of PP2A activity,
the effector of the pathway, were directly correlated
(Fig. 2f ). McGrath et al., showed lower levels of
TRAIL in the serum of IPF patients, though they did
not examine signalling downstream of TRAIL [12] .
More recent studies have shown elevated levels of
TRAIL in airway epithelial cells isolated from active
regions within IPF lungs [34] which is in line with
our findings of increased MID1 and decreased PP2A
activity in lung biopsies. Furthermore, post-hoc ana-
lysis of Schiller et al.’s recent proteomic profile in-
cluding eleven IPF patient biopsies vs three healthy
Fig. 3 Wild-type mice treated with the PP2A activator AAL(s) and Tnfsf10−/− mice were protected from increases in Mid1 mRNA, and the loss of
PP2A activity and lung function induced by bleomycin. Mid-1 mRNA was downregulated in AAL(s) treated WT mice and Tnfsf10−/− mice exposed
to bleomycin (a) while PP2A activity was increased (b). The vital capacity (VC) and pressure at the peak of compliance (Cpk) were both decreased
by bleomycin 21 days post exposure but Tnfsf10−/− mice or those treated with AAL(s) were protected (c-d). n = 5–8, * p < 0.05
Collison et al. BMC Pulmonary Medicine           (2019) 19:31 Page 6 of 11
controls demonstrates MID1 to be significantly upreg-
ulated [35] (supplementary table s1 p = 0.012).
Our study expands on the previous studies by showing
MID1 protein upregulation in IPF lung tissue and char-
acterising the downstream signalling pathways affected
by it in the form of reduced phosphatase activity of
PP2A. Of particular interest, is the association of PP2A
activity levels with a decline in DLco. This suggests that
there may be a causal relationship to IPF pathogenesis
supporting potential modulation of activity or the nega-
tive regulator E3 ubiquitin ligase MID1 as a therapeutic
target. In support of this are our observations that
AAL(s) treated WT mice and Tnfsf10−/− mice were pro-
tected from bleomycin-induced fibrosis. However, these
data contrast with the previous McGrath et al., study
that demonstrated an increase in bleomycin-induced fi-
brosis in Tnfsf10−/− mice [12]. McGrath et al., used fe-
male mice on a C57BL/6 background while we used
male mice on a BALB/c background suggesting the
mouse strain or gender may exert a significant influence
on the bleomycin model in the absence of TRAIL. This
is of interest as IPF is biased towards males though the
reason for this is unknown [36]. We have also found that
female Tnfsf10−/− mice on a BALB/c background to
spontaneously develop lung fibrosis associated with the
small airways later in life [28], though these changes
themselves may be due to alterations in the microbiome
with repeated unfiltered room air exposures in the
models used [28, 37]. Together, this suggests that there
may be gender specific roles for either inflammatory or
apoptotic TRAIL signalling that also play a role in lung
fibrosis and is worthy of further investigation. It also
highlights that experimental data from murine models
need to be interpreted in the context of disease observed
in patients where TRAIL and its downstream signalling
pathway is augmented.
The complexity of the gender and strain influences ob-
served in in-vivo models lead us to follow a more reduc-
tionist approach and conduct in-vitro cell culture
experiments. This approach was previously employed to
demonstrate that MID1-PP2A signalling is induced in
primary human epithelial cells in the presence of recom-
binant TRAIL [22]. In fibrotic lung models TRAIL has
been shown to be broadly expressed by multiple cells
types including epithelial cells, endothelial cells, fibro-
blasts and alveolar macrophages [12, 17, 22, 28, 38].
Here we have demonstrated in cultured primary fibroblasts
recombinant TRAIL directly induced both proliferation
Fig. 4 Wild type mice treated with AAL(s) and Tnfsf10−/− mice had reduced expression of collagen-α2(I) (a), TGFβ (b), mmp9 (c) and ccl2 (d) in
their lungs 21 days after bleomycin exposure. n = 7–12, * p < 0.05
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and the production of collagen in a dose dependent manner
(Fig. 6). Furthermore, AAL(s) inhibited collagen expression
without affecting Mid1 expression in-vitro. In contrast
AAL(s) treated WT mice showed reduced Mid1 expression.
This supports our proposal that PP2A is downstream of
Mid1 on a cellular level while the effect of PP2A activation
on Mid1 expression in-vivo occurs because of a blunted in-
flammatory and pro-fibrotic lung response involving a
complex interaction between multiple cell types that cannot
be replicated in isolated cells in-vitro. Thus, this combin-
ation of ex-vivo and in-vivo studies add further mechanistic
support to a role for Mid1 in the promotion of fibrosis.
The key role for MID1 in fibrosis suggests this path-
way may be suitable as a therapeutic target. The FTY720
analogue Fingolimod is undergoing phase 2 and phase 3
clinical trials involving patients with relapsing and
relapsing-remittent multiple sclerosis [39], and was gen-
erally well tolerated at the approved dose [40]. However,
Fig. 5 AAL(s) treated wild type mice and Tnfsf10−/− mice were protected from bleomycin-induced collagen deposition and apoptosis. Collagen
deposition in Masson’s trichrome stained lung sections (a). Images at 200x magnification of representative sections from Masson’s trichrome for
(b) Wild Type saline and (c) bleomycin treated (d) wildtype bleomycin treated with AAL(s), (e) TRAIL−/− bleomycin treated and (f) TRAIL −/− saline.
Apoptosis in terms of the percentage of TUNEL positive cells in lung sections (g), which peaked at one day post bleomycin but was still significantly
elevated after day 21(h). n = 6, * p < 0.05
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FTY720 in its phosphorylated form is also a sphingosine
1-phospate receptor modulator, which inhibits lympho-
cyte migration and results in lymphopenia. Therefore,
non-phosphorylatable FTY720 analogues such as AAL(s)
and small molecules targeting MID1 may be more suit-
able for clinical trials in IPF patients, should any be
available in the future.
A limitation of our study was that the diagnosis of IPF
in these participants was reliant on transbronchial biop-
sies which is not in accordance with current clinical
guidelines. To address the unknown specificity of our
approach we excluded the possibility of IPF participants
being incorrectly classified as controls by using control
tissues distal to resected lung cancer in patients with no
clinical evidence of IPF or other fibrotic lung disease. In
regard to the unknown specificity of using transbron-
chial biopsies for the diagnosis of IPF our approach
could have resulted -if anything- in a smaller difference
in MID1 between IPF patients and controls in our study.
However, despite this limitation, we found a significant
difference in serum TRAIL, tissue MID1 and a trend in
PP2A between groups which is suggestive of consistent
and robust data. Though further studies utilising tissue
from a population with clinical diagnosis according to
the most recent Fleischner Society White Paper [41]
could now be warranted to precisely identify which pa-
tients would most benefit from novel therapeutics tar-
geting MID1.
Conclusions
TRAIL signalling through MID1 deactivates PP2A and
promotes fibrosis with corresponding lung-function de-
cline. This may provide novel therapeutic targets for IPF.
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